News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Subscribe To Our Newsletter & Stay Updated
